v3.25.1
Schedule of Operating Financial Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Net sales $ 6,719 $ 5,443
Cost of goods sold 1,013 888
Gross profit 5,706 4,555
Operating expenses    
Research and development 642 399
Total operating expenses 9,528 8,404
Loss from operations (3,822) (3,849)
Other (income) expense    
Interest and other income 83 225
Other expense 164 4
Loss before income taxes (3,903) (3,628)
Benefit from income taxes (48) (122)
Net loss (3,855) (3,506)
Bioelectronic Innovations Segment [Member]    
Segment Reporting Information [Line Items]    
Net sales [1] 6,719 5,443
Cost of goods sold 1,013 888
Gross profit 5,706 4,555
Operating expenses    
Research and development 642 399
General and administrative 4,333 3,884
Sales and marketing 4,553 4,121
Total operating expenses 9,528 8,404
Loss from operations (3,822) (3,849)
Other (income) expense    
Interest and other income (83) (225)
Other expense 164 4
Total other (income) expense 81 (221)
Loss before income taxes (3,903) (3,628)
Benefit from income taxes 48 122
Net loss $ (3,855) $ (3,506)
[1] See Note 4 Revenue for geographical and disaggregation information.